Streetbeat News

Stock Prices

OWLT

Owlet Inc. (OWLT) reported a narrower loss of $(0.70) per share in Q3 compared to $(2.38) per share in the same quarter last year, indicating an improvement in earnings. However, sales declined to $9.20 million from $17.36 million in the same period, representing a significant decrease in revenue year-over-year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:08 pm

SALM

Salem Media Group anticipates a decrease in total revenue of 6-8% for Q4 compared to the same period in 2022, signaling potential challenges in its business operations or market conditions.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:08 pm

RUM

Rumble Inc. (RUM) reported a significant increase in Q3 losses to $(0.14) per share compared to $(0.01) last year, and missed sales estimates with $17.98M against the expected $25.36M. However, sales grew by 63.73% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:08 pm

ICAD

iCAD Inc. (NASDAQ:ICAD) reported Q3 2023 earnings with a GAAP EPS of $(0.05), surpassing the $(0.08) estimate, marking a 37.5% beat and a 66.67% improvement from last year's $(0.15) per share. However, sales of $4.07M fell short of the $6.27M estimate by 35.04%, and were down 35.92% from $6.36M in the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 13, 2023 | 9:07 pm

SALM

Salem Media Group reported Q3 total revenue of $63.5 million, falling short of the estimated $65.235 million.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:07 pm

EXFY

A Form 4 filing with the SEC reveals that SF Roofdeck GP LLC purchased 1,014,197 shares of Expensify's common stock at a price of $1.82 per share.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:06 pm

YMAB

Y-mAbs Therapeutics reported a 59% year-over-year increase in Q3 net product revenues for DANYELZA, totaling $20 million. This growth indicates a strong market uptake and positive performance for the company's product.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:06 pm

CARA

Cara Therapeutics (NASDAQ:CARA) reported Q3 2023 GAAP EPS of $(0.52), which was in line with analyst estimates, but represented a 20.93% decrease from the previous year. Sales of $4.87M fell short of the $9.95M estimate, a 51.10% miss and a 55.00% decrease from the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 13, 2023 | 9:06 pm

ANF

Abercrombie & Fitch (NYSE:ANF) received 8 analyst ratings in the last quarter, with an average price target of $56.0, which is below the current price of $66.8, suggesting a downside. The average price target has increased by 32.42% from the previous target of $42.29. The ratings were split evenly with 4 somewhat bullish and 4 indifferent, with no bullish or bearish ratings.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 9:01 pm

WELL

Welltower (NYSE:WELL) received 9 analyst ratings in the last quarter, with an average 12-month price target of $90.89, a high of $101.00, and a low of $83.00. The current average price target represents a 6.39% increase from the previous average of $85.43. The ratings included 2 bullish, 4 somewhat bullish, and 3 indifferent, with no bearish or somewhat bearish ratings. Analysts typically review stocks quarterly or after major company updates, basing their ratings on financial predictions and company performance.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 9:00 pm